Physician profile
Daniel Taylor
NPI 1770076663
$1,639.90
in general payments reported to CMS, 2019-2025
31 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $541 · 2023: $303 · 2024: $188 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $298.05 | 2021-2025 | Tagrisso |
| Stryker Corporation | $172.45 | 2025 | Optablate |
| Takeda Pharmaceuticals U.S.A., INC. | $148.02 | 2022-2024 | Iclusig |
| Abbvie INC. | $127.44 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $85.14 | 2022-2024 | |
| Genentech USA, INC. | $79.80 | 2023-2024 | Lunsumio, Polivy, Columvi |
| Amgen INC. | $66.12 | 2022-2023 | Kyprolis, Blincyto |
| Genzyme Corporation | $56.01 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $48.05 | 2023 | Imbruvica, Epkinly |
| Seagen INC. | $46.28 | 2022-2023 | Tukysa |
| Karyopharm Therapeutics INC. | $45.14 | 2022-2023 | Xpovio |
| Gilead Sciences, INC. | $42.97 | 2021 | |
| Glaxosmithkline, LLC. | $40.40 | 2022 | |
| Coherus Oncology, INC. | $39.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $38.89 | 2024 | Opdivo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $32.51 | 2022-2023 | Monoferric |
| Jazz Pharmaceuticals INC. | $24.53 | 2021 | |
| Daiichi Sankyo INC. | $22.64 | 2021 | |
| Beigene USA, INC. | $22.12 | 2023 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $20.71 | 2024 | Qinlock |
| Alexion Pharmaceuticals, INC. | $19.82 | 2022 | |
| Servier Pharmaceuticals LLC | $18.72 | 2024 | |
| Rigel Pharmaceuticals, INC. | $18.56 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.51 | 2021 | |
| G1 Therapeutics, INC. | $18.37 | 2023 | Cosela |
| Novo Nordisk INC | $15.92 | 2023 | Novoeight, Rebinyn, Novoseven |
| Incyte Corporation | $15.72 | 2021 | |
| Emmaus Medical, INC. | $14.83 | 2022 | |
| Foundation Medicine, INC. | $14.76 | 2023 | |
| Pfizer INC. | $13.91 | 2022 | |
| Janssen Biotech, INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.